Ardelyx (ARDX) Non-Current Debt (2018 - 2026)
Ardelyx's (ARDX) quarterly Non-Current Debt came in at $203.5 million in Q1 2026, up 34.51% YoY from $151.3 million in Q1 2025, and little changed on a QoQ basis from $202.8 million in Q4 2025.
Ardelyx (ARDX) Non-Current Debt (2018 - 2026) Analysis & Trends
Ardelyx (ARDX) has 9 years of Non-Current Debt data on file, last reported at $203.5 million in Q1 2026.
- Quarterly Non-Current Debt rose 34.51% year-over-year to $203.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $203.5 million (up 34.51% YoY) and the FY2025 annual result came in at $202.8 million, up 34.46% from the prior year.
- Non-Current Debt steadied at $203.5 million in Q1 2026, from $202.8 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $203.5 million in Q1 2026 to a low of $26.1 million in Q1 2022.
- A 5-year average of $112.1 million and a median of $100.5 million in 2024 frame the typical range for Non-Current Debt.
- The widest YoY moves for Non-Current Debt: up 277.43% in 2022, down 23.9% in 2022.
- Tracing ARDX's Non-Current Debt over 5 years: stood at $26.5 million in 2022, then soared by 87.72% to $49.8 million in 2023, then soared by 202.78% to $150.9 million in 2024, then soared by 34.46% to $202.8 million in 2025, then grew by 0.34% to $203.5 million in 2026.
- The last three Non-Current Debt figures came in at $203.5 million (Q1 2026), $202.8 million (Q4 2025), and $202.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 251.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 251.82 Mn |
| Mar 31, 2026 | 203.52 Mn |
| Dec 31, 2025 | 202.83 Mn |
| Sep 30, 2025 | 202.14 Mn |
| Jun 30, 2025 | 201.45 Mn |
| Mar 31, 2025 | 151.30 Mn |
| Dec 31, 2024 | 150.85 Mn |
| Sep 30, 2024 | 100.71 Mn |
| Jun 30, 2024 | 100.25 Mn |
| Mar 31, 2024 | 99.83 Mn |
| Dec 31, 2023 | 49.82 Mn |
| Sep 30, 2023 | 27.23 Mn |
| Sep 30, 2022 | 26.54 Mn |
| Jun 30, 2022 | 26.37 Mn |
| Mar 31, 2022 | 26.14 Mn |
| Sep 30, 2021 | 7.03 Mn |
| Jun 30, 2021 | 15.13 Mn |
| Mar 31, 2021 | 34.35 Mn |
| Dec 31, 2020 | 46.62 Mn |
| Sep 30, 2020 | 50.68 Mn |